Vitamin D dynamics predict treatment response to intravenous glucocorticoids in thyroid-associated ophthalmopathy: a retrospective cohort study

Background: Intravenous glucocorticoids (IVGC) represent first-line therapy for active moderate-to-severe thyroid-associated ophthalmopathy (TAO). The relationship between vitamin D (VitD) and IVGC efficacy in TAO remains undefined. Methods: This retrospective study grouped TAO patients completing IVGC therapy with standardized VitD/calcium supplementation at First Affiliated Hospital of Xi'an Jiaotong University (2015-2019). Serum 25-hydroxyvitamin D (25(OH)D) and bone markers were measured pre/post-treatment. Multivariate regression and ROC analysis identified predictors. Results: = 0.006), with an optimal cutoff of +2.7 ng/mL. Predictive power was enhanced in males, patients ≥50 years, and baseline 25(OH)D -deficient subgroups. Conclusion: Δ25(OH)D is an independent predictor of IVGC response in TAO. Monitoring dynamic changes in serum 25(OH)D during therapy and targeting a minimum increase of 2.7 ng/mL may be associated with improved treatment outcomes, particularly in male, elderly, and VitD-deficient subpopulations.